EuroLife Brands establishes European advisory council to help drive growth

Dr Heinz Schönleber, Josed Spaeth and Eckart Keil have joined as independent advisors, the group said

These three individuals bring together impressive resumes which will enable EuroLife to advance its business objectives on a more timely and efficient basis

Inc () (OTCMKTS:EURPF), the cannabis-focused group, has formed a panel of expert European advisors to help the company realise its business aims. 

Dr Heinz Schönleber, Josed Spaeth and Eckart Keil have joined as independent advisors to offer their expert knowledge on hemp product(s), agriculture and finance, the firm said in a statement. 

READ: EuroLife Brands to refresh Aphria's education portal

Keil is an award-winning international equity and bond fund manager with more than 30 years' experience, while Dr Schönleber also has over three decades' experience in agriculture.

He founded his first agricultural enterprise in 1990 and today leads the German Schönleber Group, which has an 1,800-hectare land position in breeding and processing of agriculture and renewable raw materials.

In the last two years, it has been producing CBD from hemp, working with one of the largest and most innovative hemp farms in Europe.

Spaeth is a certified industrial designer by trade and brings extensive experience in global development and project management to EuroLife, the firm said.

International network

"His considerable international network will be invaluable to the success of EuroLife's European operations and expansion," it added.

Spaeth and Dr Schönleber are members of the board of directors of the recently formed Farmhus.de which holds the Dresden Hemp facility, in which EuroLife announced a deal in December to buy a 20% stake.

"I am very pleased to announce the formation of a European Advisory Council with such a respected group of advisors as we implement our business strategy across the European landscape," said Shawn Moniz, CEO at .

"This group of three individuals brings together impressive resumes which will enable EuroLife to advance its business objectives on a more timely and efficient basis. I look forward to working with this group as their wealth of experience, knowledge and contacts in the hemp product(s), agriculture and finance sectors, will contribute to the success of our company."

Shares zoomed up over 14% in Toronto to C$0.040.

---Updates for share price---

Contact the author at [email protected]

FSD Pharma advancing its Phase 1 study in Australi...
FSD Pharma amends deal with Solarvest BioEnergy to...

Related Posts